List of Excipients in Branded Drug TRANEXAMIC ACID IN SODIUM CHLORIDE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Exela Pharma Sciences LLC	TRANEXAMIC ACID IN SODIUM CHLORIDE	tranexamic acid	51754-0108	SODIUM CHLORIDE
Exela Pharma Sciences LLC	TRANEXAMIC ACID IN SODIUM CHLORIDE	tranexamic acid	51754-0108	WATER

Generic Drugs Containing TRANEXAMIC ACID IN SODIUM CHLORIDE

Company	Ingredient	NDC	Excipient
Fresenius Kabi USA LLC	tranexamic acid	65219-534	SODIUM CHLORIDE
Fresenius Kabi USA LLC	tranexamic acid	65219-534	WATER
HP Halden Pharma AS	tranexamic acid	66298-5340	SODIUM CHLORIDE
HP Halden Pharma AS	tranexamic acid	66298-5340	WATER

What are the Most Frequently-Used Excipients in TRANEXAMIC ACID IN SODIUM CHLORIDE?

# Of NDCs	Excipient
5	SODIUM CHLORIDE
5	WATER

Tranexamic Acid in Sodium Chloride: Excipient Strategy, Patent Position and Commercial Opportunities

Last updated: September 8, 2026

Tranexamic acid in sodium chloride is a mature small-molecule injectable product with limited active-ingredient patent risk and meaningful opportunities in ready-to-administer hospital products. The commercial advantage comes from container design, stability, sterility assurance, supply reliability, dosing convenience and hospital-pharmacy economics rather than from new excipient chemistry.

Premixed presentations typically use tranexamic acid in 0.7% sodium chloride at concentrations such as 10 mg/mL or 20 mg/mL. The formulation is intentionally simple: tranexamic acid, sodium chloride, Water for Injection and pH adjustment, if required. Product differentiation can come from premixed bags, smaller-volume containers, terminal sterilization, extended in-use stability and packaging compatible with automated hospital workflows.

What is tranexamic acid in sodium chloride?

Tranexamic acid is a synthetic lysine analogue that inhibits plasminogen activation and reduces fibrinolysis. The injectable product is used in settings including major bleeding, trauma, postpartum hemorrhage and selected surgical procedures. The FDA-approved injectable reference product, Cyklokapron, is supplied as tranexamic acid injection rather than as a universal sodium chloride premix [1].

A sodium chloride premix is designed to eliminate bedside dilution. Relevant presentations may include:

Product attribute	Commercially relevant range or approach
Active ingredient	Tranexamic acid
Vehicle	Sodium chloride solution
Common premix concentration	10 mg/mL or 20 mg/mL
Typical container	100 mL flexible bag or ready-to-use container
Primary route	Intravenous infusion
Key quality attributes	Assay, pH, particulate matter, sterility, endotoxin, visible appearance
Main users	Hospitals, emergency departments, operating rooms, obstetric units and trauma centers
Regulatory category	Small-molecule injectable drug, generally approved through an NDA or ANDA pathway

Exact concentrations, container sizes and labeling differ by manufacturer and jurisdiction. The commercial product must be evaluated against its specific approved label and regulatory listing.

What excipients are used in tranexamic acid sodium chloride injection?

The core excipient strategy is minimal. Sodium chloride is both the tonicity agent and the infusion vehicle. Water for Injection is the solvent. The formulation may use a pH-adjusting agent, but unnecessary buffers increase compatibility and regulatory risk.

Recommended excipient architecture

Component	Function	Strategic assessment
Sodium chloride	Vehicle and tonicity control	Preferred base excipient because it is familiar, inexpensive and widely accepted for IV use
Water for Injection	Solvent	Required parenteral-grade vehicle
Hydrochloric acid or sodium hydroxide	pH adjustment	Use only as needed; avoid unnecessary ionic load
Phosphate or citrate buffer	pH control	Generally less attractive unless stability data require buffering
Antioxidant	Oxidation control	Usually unnecessary unless forced by degradation data
Preservative	Multidose microbial control	Generally unsuitable for a single-dose IV premix
Chelating agent	Metal-ion control	Potentially useful only if metal-catalyzed degradation is demonstrated
Surfactant	Solubilization	Usually unnecessary because tranexamic acid is highly water-soluble

A low-excipient formulation supports a simpler toxicological package and reduces the number of extractables, leachables and compatibility variables. It also supports a clean label and easier hospital formulary adoption.

What formulation patents protect tranexamic acid in sodium chloride?

The active ingredient is an old generic drug, so composition-of-matter patent protection is not the principal barrier. Tranexamic acid was discovered and commercialized decades ago, and the basic active-ingredient patent estate has long since expired.

The relevant intellectual-property questions concern:

1. Specific premixed concentrations.
2. Container and closure systems.
3. Sterile manufacturing processes.
4. Stability claims.
5. Methods for reducing preparation errors.
6. Ready-to-use emergency or obstetric presentations.
7. Device combinations, including infusion systems.
8. Regional formulation patents outside the United States.

A sodium chloride premix can still be covered by a later patent if a claim requires a narrowly defined concentration, pH range, container material, oxygen-control system or stability profile. A generic formulation is not automatically free of all patent risk merely because tranexamic acid is off patent.

Patent-strength assessment

IP category	Expected strength for a standard premix	Commercial relevance
Tranexamic acid composition of matter	Very low	Does not block generic entry
Standard sodium chloride vehicle	Very low	Widely used, difficult to protect broadly
Specific concentration	Low to moderate	May support narrow formulation claims
Container system	Moderate in selected cases	Can protect ready-to-use packaging
Sterilization or manufacturing process	Moderate	May create process-design constraints
Stability profile	Moderate if technically specific	Valuable if linked to long shelf life
Method of use	Moderate to high in narrow indications	Depends on jurisdiction and claim scope
Device or infusion integration	Moderate	Can create hospital-channel differentiation

A freedom-to-operate review should examine published applications, granted patents and patent-term adjustments in each launch jurisdiction. Patent status must be checked against the precise manufacturer, concentration, container and use case.

When does tranexamic acid lose exclusivity?

Tranexamic acid itself has lost primary patent exclusivity. Market access is therefore governed mainly by regulatory approval, manufacturing capacity, product quality and procurement economics.

For a U.S. generic injectable, the principal regulatory pathway is an ANDA referencing the relevant listed drug. An ANDA applicant must demonstrate pharmaceutical equivalence and bioequivalence where applicable, along with manufacturing and quality compliance. For an injectable solution, formulation sameness, sterility, strength, route and container attributes are central to review [2].

FDA exclusivity can still attach to a specific new indication, formulation or clinical development program. That exclusivity would not restore broad composition-of-matter protection for the active ingredient.

Exclusivity timeline

Protection type	Tranexamic acid premix position
Basic active-ingredient patent	Expired
Standard generic formulation protection	Generally limited
New indication exclusivity	Possible, but indication-specific
New drug product exclusivity	Possible for a genuinely differentiated product
Regulatory exclusivity for a standard ANDA	Generally not expected
Pediatric exclusivity	Product- and sponsor-specific
Orphan exclusivity	Depends on an approved orphan indication
Biosimilar exclusivity	Not applicable

What is the Orange Book status of tranexamic acid in sodium chloride?

The Orange Book identifies approved drug products, therapeutic equivalence evaluations and certain patent or exclusivity information. A premixed sodium chloride product should be evaluated by its exact proprietary name, active ingredient, dosage form, strength, applicant and application number rather than by the broad phrase “tranexamic acid in sodium chloride” [3].

The main Orange Book questions are:

• Is the product listed as an NDA or ANDA?
• Is it therapeutically equivalent to the reference product?
• Are patents listed for the product?
• Does the listed drug have active exclusivity?
• Is the approved presentation a premix or a concentrate requiring dilution?

A standard tranexamic acid injection may be therapeutically equivalent to a reference injection while a particular premixed bag may have a separate product listing. Therapeutic-equivalence conclusions should not be inferred solely from the active ingredient.

What Paragraph IV challenges affect tranexamic acid premix products?

Paragraph IV litigation is likely to be limited for a mature tranexamic acid product unless a branded sponsor has listed patents covering a specific formulation, device or method of use. A generic applicant may certify that listed patents are invalid, unenforceable or not infringed. The commercial significance of a Paragraph IV filing depends on whether the patent is actually listed against the target product.

For a standard sodium chloride premix, likely disputes would focus on:

• The scope of formulation claims.
• Stability data and claimed shelf life.
• Container or bag construction.
• Method-of-use claims for a defined patient population.
• Whether the generic product is materially different from the patented formulation.

No biosimilar pathway applies. Tranexamic acid is a chemically synthesized small molecule, not a biologic. Competitive entry occurs through generic or hybrid-drug pathways, not biosimilar approval.

How should the excipient strategy be optimized?

The optimal formulation should prioritize chemical stability, particulate control, sterilization compatibility and supply continuity.

Sodium chloride concentration

A 0.7% sodium chloride vehicle can provide a commercially useful balance between tonicity and product differentiation. A standard 0.9% sodium chloride vehicle may be more familiar to hospitals but can create a less differentiated product and may not match the intended finished-product specification.

The selected sodium chloride concentration should be assessed for:

• Osmolality.
• Infusion tolerability.
• Compatibility with common IV lines.
• Container permeability.
• Precipitation risk after admixture.
• Labeling consistency with clinical dosing instructions.

pH control

Tranexamic acid injection labels commonly specify a mildly acidic to near-neutral pH range. Excessive buffering can increase degradation pathways, alter compatibility or complicate regulatory comparability. The preferred approach is to establish the natural formulation pH, then adjust only when necessary for stability or tolerability.

Preservatives

A single-dose, ready-to-use IV bag should generally avoid preservatives. Preservatives can create toxicity concerns, especially in neonates and critically ill patients, and can restrict hospital use. A preservative-free claim is commercially valuable if supported by validated container-closure integrity and aseptic or terminal sterilization controls.

Antioxidants and chelators

Antioxidants and chelating agents should not be included as default excipients. Their use should follow degradation-pathway evidence. Each additional excipient increases formulation complexity, analytical burden and the number of potential compatibility questions.

Container selection

Container choice may create greater commercial value than a novel excipient. Options include:

• Polyolefin bags.
• Multilayer flexible bags.
• Small-volume containers.
• Ready-to-spike systems.
• Prefilled syringes for selected emergency applications.

The container must be assessed for sorption, leachables, oxygen transmission, moisture transmission, light protection and compatibility with terminal sterilization. Plastic packaging may improve logistics but can introduce extractables and shelf-life constraints.

What manufacturing and IP barriers affect commercial entry?

The main manufacturing barriers are sterile processing and supply-chain execution, not active-ingredient synthesis.

Critical manufacturing controls

A commercial manufacturer must control:

• Water system quality.
• Bioburden before sterilization.
• Sterility assurance.
• Endotoxin.
• Particulate matter.
• Fill-volume accuracy.
• Container-closure integrity.
• Mixing homogeneity.
• pH and osmolality.
• Stability through the proposed shelf life.

Where feasible, terminal sterilization can offer a stronger sterility-assurance profile than aseptic processing. The formulation, bag material and closure system must tolerate the selected cycle without unacceptable degradation or package failure.

USP chapters addressing sterility, bacterial endotoxins, particulate matter and container-closure integrity are central to the development program [4]. ICH Q8, Q9 and Q10 provide the framework for pharmaceutical development, risk management and the pharmaceutical quality system [5-7].

What commercial opportunities exist for tranexamic acid sodium chloride products?

The strongest opportunities are in hospital-use convenience and supply reliability.

Ready-to-use emergency products

A premix can remove bedside dilution steps in trauma, obstetrics and surgery. This reduces preparation time and may reduce compounding errors. A 100 mL bag with a standardized dose can fit emergency department and operating-room protocols.

Obstetric hemorrhage

Postpartum hemorrhage is a high-value use case because treatment speed matters and hospital protocols are often standardized. A dedicated presentation with clear dosing, rapid identification and compatibility information can compete on workflow efficiency rather than molecule price.

Trauma and surgery

Trauma centers and surgical hospitals may prefer a product that can be stocked in automated dispensing cabinets and administered without pharmacy dilution. Supply continuity is important because demand can rise during mass-casualty events.

Contract manufacturing and private-label supply

A manufacturer with sterile-bag capacity can offer private-label tranexamic acid premixes to hospital suppliers, group purchasing organizations and regional distributors. The product is suitable for a platform approach using the same container and manufacturing process across several strengths.

Geographic expansion

The commercial case is strongest in jurisdictions where:

• Injectable tranexamic acid is included in hospital protocols.
• Premixed bags are preferred over ampules or vials.
• Emergency and obstetric demand is substantial.
• Local sterile manufacturing capacity is limited.
• Government or hospital tenders reward supply reliability.

U.S., European, Australian, Canadian and selected emerging-market strategies will differ in presentation requirements, pharmacopoeial standards, registration pathways and tender economics.

How does tranexamic acid premix compare with vial and ampule products?

Attribute	Premixed sodium chloride bag	Concentrate vial	Ampule
Bedside dilution	Not required	Usually required	Usually required
Preparation time	Low	Moderate	Moderate
Packaging cost	Higher	Lower	Low to moderate
Dosing flexibility	Moderate	High	High
Error-reduction potential	High	Moderate	Moderate
Shipping efficiency	Lower	Higher	Higher
Hospital pharmacy workload	Lower	Higher	Higher
Differentiation potential	Higher	Low	Low
Patentability potential	Higher but narrow	Limited	Limited

The premix is unlikely to win solely on unit price. Its value proposition must include lower preparation burden, lower medication-error exposure, reduced pharmacy handling and dependable availability.

What litigation and settlement risks should manufacturers assess?

A standard tranexamic acid premix has a lower litigation profile than newer specialty injectables, but risk can arise from product-specific patents and regulatory exclusivity.

The diligence file should review:

• Orange Book patent listings.
• Published Paragraph IV notices.
• Federal district court litigation.
• FDA approval letters.
• Patent assignments and licenses.
• Settlement agreements affecting generic launch dates.
• Device patents covering infusion bags or connectors.
• Method-of-use patents for postpartum hemorrhage, trauma or surgery.

A licensing deal may be commercially useful where a manufacturer lacks a validated bag platform, sterilization process or hospital-distribution network. The value of a license depends on whether it grants rights to technology that materially reduces development time or protects a differentiated presentation.

What is the revenue exposure and competitive outlook?

Tranexamic acid is generally a high-volume, price-sensitive hospital product. Revenue exposure is concentrated in institutional procurement, tenders and distributor contracts rather than retail prescribing.

The main competitors are:

• Branded tranexamic acid injection.
• Generic vials.
• Generic ampules.
• Premixed IV bags.
• Hospital-compounded solutions.
• Alternative antifibrinolytic or blood-management protocols.

A premix can command a price premium over a vial if the sponsor demonstrates measurable workflow benefits. The likely commercial ceiling is constrained by generic competition and the simplicity of the formulation.

Key Takeaways

• Tranexamic acid in sodium chloride is a mature small-molecule injectable with limited active-ingredient patent risk.
• The strongest product opportunity is a ready-to-use, preservative-free premix for emergency, trauma, obstetric and surgical use.
• Sodium chloride, Water for Injection and minimal pH adjustment are the preferred excipient platform.
• Preservatives, unnecessary buffers, antioxidants and chelators should be avoided unless supported by formulation data.
• Container design, sterilization, shelf life and supply reliability offer more defensible differentiation than excipient novelty.
• Biosimilar risk is not applicable because tranexamic acid is a chemically synthesized small molecule.
• Orange Book, ANDA, patent-listing and Paragraph IV analysis must be performed for the exact product presentation.
• Commercial success depends on hospital workflow, tender access, sterile manufacturing capacity and reliable supply.

FAQs

Is tranexamic acid in sodium chloride a new chemical entity?

No. Tranexamic acid is an established small molecule. A sodium chloride premix is a drug-product formulation and does not create new active-ingredient exclusivity.

Can a tranexamic acid premix receive new FDA exclusivity?

Potentially, but only if the product qualifies through a specific new indication, formulation, clinical development program or other statutory pathway. A routine generic premix generally does not receive broad exclusivity.

Is 0.7% sodium chloride preferable to 0.9% sodium chloride?

Neither concentration is universally preferable. The selection depends on the target osmolality, approved formulation, stability, compatibility and clinical labeling strategy. A 0.7% vehicle can provide differentiation, while 0.9% sodium chloride may offer greater institutional familiarity.

What is the most defensible intellectual property for a premixed tranexamic acid bag?

Narrow claims covering a defined concentration, pH range, container system, stability profile, sterilization process or device combination are more plausible than broad claims covering tranexamic acid in sodium chloride.

Are hospital-compounded tranexamic acid solutions a major competitor?

Yes. Hospital compounding can compete with commercial premixes where pharmacy capacity is available. A commercial product must justify its price through convenience, reduced preparation risk, validated shelf life and consistent supply.

References

1. U.S. Food and Drug Administration. (2023). Cyklokapron (tranexamic acid) injection prescribing information.
2. U.S. Food and Drug Administration. (2024). Abbreviated new drug application (ANDA): Generics.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary: Sterility, bacterial endotoxins, particulate matter and container-closure integrity chapters.
5. International Council for Harmonisation. (2009). ICH Q8(R2): Pharmaceutical development.
6. International Council for Harmonisation. (2023). ICH Q9(R1): Quality risk management.
7. International Council for Harmonisation. (2008). ICH Q10: Pharmaceutical quality system.